About Immunovant
Immunovant news and updates
Immunovant, Inc. partners with Harbour Biomed
It is being developed in the US/Europe and China respectively by global license partners Immunovant and Harbour Biomed.
Jan 1, 2022 | hanall.co.krImmunovant, Inc. launches next-generation anti-FcRn, IMVT-1402
Immunovant Inc. has announced a next-generation anti-FcRn, IMVT-1402, for autoimmune diseases.
Sep 29, 2022 | bioworld.comImmunovant, Inc. received financing of $75M in funding on Oct 4th 22'.
On Tuesday this week, Immunovant boosted investor sentiment even higher after announcing that they had secured $75 million in funding from the sale of shares in an underwritten offering.
Oct 6, 2022 | 247wallst.comImmunovant, Inc. is developing HL161ANS
Immunovant, a HanAll’s licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level Batoclimab (formerly known as HL161BKN) and HL161ANS originated from HanAll.
Oct 12, 2022 | medicaex.comImmunovant, Inc. launched IMVT-1402 on Sep 29th 22'.
Immunovant: At Roivant's Investor Day on September 28, Immunovant unveiled IMVT-1402, a next generation anti-FcRn which showed deep IgG lowering similar to batoclimab with no or minimal impact observed on albumin and LDL levels in a head-to-head animal study with batoclimab and placebo.
Nov 13, 2022 | cmocro.com